Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KOD
SELLKodiak Sciences Inc. · Healthcare · United States · $2.6B · Avg Vol: $32M/d
COMPANY DESCRIPTION
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for common retinal diseases, such as wet AMD and diabetic macular edema. The company's competitive edge lies in its proprietary KSI technology platform, which aims to create long-acting intravitreal treatments to reduce patient injection burden. It operates as a focused biotech player, leveraging its specialized platform to address significant unmet medical needs in ophthalmology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 57.2M | — |
| EPS | -5.16 | -6.39 | -4.97 | -3.35 | -4.32 | — | -4.00 | -3.74 | -3.12 | — |
| Shares | 51.8M | 52.3M | 52.5M | 52.7M | 61.8M | +19.2% | 62.6M | — | — | — |
| Debt | 80.0M | 87.7M | 81.6M | 70.3M | 59.2M | -7.3% | 56.0M | — | — | — |
| Equity | 663.3M | 436.2M | 265.8M | 150.3M | 157.4M | -30.2% | — | — | — | — |
| Op CF | -182.3M | -206.5M | -154.2M | -117.3M | -136.0M | — | -146.9M | — | — | — |
| Inv CF | -38.8M | -336.5M | 249.2M | -0.8M | -0.5M | — | — | — | — | — |
| Fin CF | 8.2M | 1.9M | 31.0K | 0.5M | 178.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KOD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc.(you) | $2.6B | 27 | SELL |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.6B | 26 | SELL |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.6B | 28 | SELL |
| CLDX | Celldex Therapeutics, Inc. | $2.8B | 24 | SELL |
| ATAI | AtaiBeckley Inc. | $2.7B | 31 | SELL |
| NUVB | Nuvation Bio Inc. | $2.2B | 28 | SELL |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | 30 | SELL |
| IRON | Disc Medicine, Inc. | $2.8B | 23 | SELL |
| SION | Sionna Therapeutics, Inc. | $2.1B | 28 | SELL |
| NKTR | Nektar Therapeutics | $2.4B | 22 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%